You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TP53 gene

Showing 1 - 25 of 8,274
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome Trial in Boston (Data and Specimen Collection)

Recruiting
  • Li-Fraumeni Syndrome
  • +4 more
  • Data and Specimen Collection
  • Boston, Massachusetts
  • +2 more
Jan 23, 2023

p53 and Response to Preoperative Radiotherapy for T2 and T3

Recruiting
  • Rectal Cancer
  • preoperative short course radiation
  • Vienna, Austria
    Medical University of Vienna, Department of Surgery
Apr 6, 2022

Acute Myeloid Leukemia Trial in Columbus (Decitabine, Nivolumab, Venetoclax)

Suspended
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 5, 2022

Patogenic Mutation in 5 Genes

Completed
  • Colorectal Cancer
  • +5 more
  • co-occuring mutation
  • Jakarta, ALL, Indonesia
    Vania Myralda Giamour Marbun
Jul 21, 2021

Adult Solid Tumor, Bladder Carcinoma, Colon Carcinoma Trial in Duarte (Laboratory Biomarker Analysis, Modified Vaccinia Virus

Active, not recruiting
  • Adult Solid Neoplasm
  • +16 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation Trial in Bergen (Cyclophosphamide)

Terminated
  • Colorectal Cancer Metastatic
  • +2 more
  • Bergen, Norway
    Haukeland University Hospital
Jan 20, 2021

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting
  • Hematologic Malignancy
  • +21 more
  • (no location specified)
Feb 9, 2023

Myeloid Leukemia, MDS Trial (IFN-?)

Not yet recruiting
  • Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Nov 15, 2023

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Clinical and Genetic Studies of Li-Fraumeni Syndrome

Recruiting
  • Li-Fraumeni Syndrome
  • +2 more
    • Bethesda, Maryland
    • +1 more
    Jan 25, 2023

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023

    Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

    Not yet recruiting
    • Aumolertinib
    • +4 more
    • (no location specified)
    Mar 8, 2023

    Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Nov 14, 2023

    Patients With Breast Cancer and Pathogenic Variants of TP53

    Completed
    • Breast Cancer
    • +3 more
    • No intervention in this study
    • São Paulo, Brazil
      ICESP
    Aug 5, 2022

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023

    NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +5 more
    • Autologous, engineered T Cells targeting TP53 R175H
    • Duarte, California
      City of Hope
    May 17, 2023

    Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • +3 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Oct 25, 2023

    Non-small Cell Carcinoma, EGFR Gene Mutation Trial in Guangzhou (Osimertinib 80 MG [Tagrisso], Pemetrexed 500 MG Injection,

    Not yet recruiting
    • Non-small Cell Carcinoma
    • EGFR Gene Mutation
    • Osimertinib 80 MG [Tagrisso]
    • +2 more
    • Guangzhou, Guangdong, China
      Department of Medical Oncology,Cancer Center of Sun Yat-Sen Univ
    Jan 3, 2021

    Li-Fraumeni Syndrome, Li-Fraumeni-Like Syndrome Trial in Philadelphia (No Intervention)

    Recruiting
    • Li-Fraumeni Syndrome
    • Li-Fraumeni-Like Syndrome
    • No Intervention
    • Philadelphia, Pennsylvania
    • +1 more
    Jan 2, 2022

    AML, Adult Trial in Berne (HDM201, Midostaurin)

    Terminated
    • AML, Adult
    • Berne, Switzerland
      Departement of Medical Oncology, University Hospital Berne
    Oct 3, 2022

    Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Ancona, Italy
    • +10 more
    Mar 14, 2023

    Endometrial Cancer Trial (Navtemadlin, Navtemadlin Placebo)

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Mar 21, 2023

    Tumors, Ovarian Cancer, Breast Cancer Trial in Houston (ZN-c3, Bevacizumab, Pembrolizumab)

    Not yet recruiting
    • Tumors
    • +4 more
    • Houston, Texas
      MD Anderson Cancer Center
    Jun 20, 2022

    MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)

    Terminated
    • MDS
    • Myelodysplastic Syndromes
    • APR-548 + Azacitidine
    • Tampa, Florida
    • +3 more
    Jul 20, 2022

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Decitabine and

    Not yet recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Decitabine and Cedazuridine
    • +2 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    May 25, 2022